Who is sponsoring NCT03561324?

NCT03561324 is sponsored by University of Arkansas.

What drugs are being tested in NCT03561324?

Interventions in NCT03561324: Imaging Beta Probe (IBP).

What condition does NCT03561324 study?

NCT03561324 studies Head and Neck Neoplasms.

Is NCT03561324 still recruiting?

NCT03561324 is currently withdrawn. Last updated 29 January 2020.

Last reviewed 2020-01-29 · How we verify

NCT03561324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Imaging of a PET Positive Lymph Node(s) Using 18FDG and a Dual-Mode, Hand-Held Intraoperative Imager

Withdrawn NA Last updated 29 January 2020

What this trial tests

NA trial testing Imaging Beta Probe (IBP) in Head and Neck Neoplasms. Withdrawn.

Timeline

20 June 2018

Primary endpoint
22 January 2020

22 January 2020

Quick facts

Lead sponsor	University of Arkansas
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Start date	20 June 2018
Primary completion	22 January 2020
Estimated completion	22 January 2020
Sites	1 location across United States

Drugs / interventions tested

Imaging Beta Probe (IBP)

Conditions studied

Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →

Sponsor

University of Arkansas

Who can join

Adults 18 to 90, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective collection of data utilizing the Imaging Beta Probe (IBP) in patients with positron emission tomography (PET) positive disease. A pilot clinical study involving 5 patients will be conducted using the IBP. The sterilized IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins. The outcome of each of these studies will be documented and used to demonstrate clinical benefits of the new probe. The investigators will correlate the images from the probe of the Fludeoxyglucose (18FDG) positive tissue, both in-vivo and ex-vivo after dissection, with the previously performed PET scan and with the routine pathology results obtained on the surgical specimens.The experimental imaging modality studied in this protocol will be compared to clinically utilized modalities of ultrasound and PET/ CT. Localization between imaging modalities will be compared with respect to: detection and side of localization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Head and Neck Neoplasms

Currently open trials in the same condition.

NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting

Other University of Arkansas trials

Trials by the same sponsor.

NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03561324 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
Last refreshed: 29 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03561324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing